1. Pink Sheet
  2. >>Geography
  3. >>Europe

EU’s New Health Crisis Response Body ‘Won’t Duplicate’ Work Of EMA And ECDC

Collaboration And Synergy Are Key To Tackling Health Emergencies

 
• By Ian Schofield

The directors of two key EU agencies outlined how they would work with the new HERA, and how they see their new roles under draft legislation aimed at strengthening their responses to health crises, at the recent European Health Forum Gastein conference. The European Medicines Agency also flagged up the potential role of real-world evidence in monitoring the safety and effectiveness of COVID-19 vaccines.

Corona Virus symbol on blue yellow european union EU flag europe background. Cornavirus COVID-19 global outbreak pandemic epidemic medical concept.
Collaboration is key in tackling pandemics and other health crises in the EU • Source: Alamy

The European Medicines Agency says it plans to work closely with the new Health Emergency Response Authority (HERA) that has been created by the European Commission to make sure the EU is prepared for future health crises.

“We very much welcome HERA. We think that this is an important EU initiative,” said Emer Cooke, the EMA’s executive...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

 
• By Neena Brizmohun

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.

EU Pharma Reform: Council Wants Strengthened Member State Powers On Drug Supply

 
• By Eliza Slawther

The Council of the EU’s vision for the pharma reform package includes a stronger role for member states regarding the supply of medicines and the prevention of indication-stacking for orphan drugs.

EU Sees Unified Pathway For Drug/IVD Studies As Key To Future Research Investment

 
• By Vibha Sharma

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.

EU CHMP Opinions And MAA Updates

 
• By Neena Brizmohun

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

More from Geography

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

 
• By Neena Brizmohun

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.

EU Pharma Reform: Council Wants Strengthened Member State Powers On Drug Supply

 
• By Eliza Slawther

The Council of the EU’s vision for the pharma reform package includes a stronger role for member states regarding the supply of medicines and the prevention of indication-stacking for orphan drugs.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.